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Abstract
Post-transplant sinusoidal fibrosis (SF) and pericellular fibrosis (PCF) have not been extensively investigated in
adults. Fifty-two post-transplant liver biopsies from 28 consented patients (12 men, mean age 49, range 33–67 years)
were studied. Tissue morphology, including an arbitrary summative fibrosis score was assessed in detail. Collagen
proportionate area (CPA) and alpha-smooth muscle actin (α-SMA) immunostain were evaluated by digital image
analysis (DIA). Anti-keratin 7, anti-C4d and anti-sonic hedgehog (Shh) immunostains were scored semi-quantitative-
ly. SF was observed in 36/52 (69.2%) biopsies and most of these (20/36, 55.6%) had centrilobular fibrosis (CLF).
PCF was seen in 7/52 (13.5%) biopsies exclusively in cases with CLF. CPA was significantly correlated with time
since liver transplantation (p = 0.043), summative fibrosis score and its main components but not with α-SMA. α-
SMA-positive area significantly correlated with the Banff rejection score (p = 0.022) and centrilobular inflammatory
changes were more severe in cases with CLF (p = 0.003). Hepatocyte ballooning of cholestatic type was associated
with PCF (p = 0.016) and Shh expression (p < 0.001). Sinusoidal fibrosis is a frequent occurrence in post-transplant
adult livers, with predilection toward centrilobular areas. Graft age and oxidative stress may contribute to SF
development, while hepatocyte ballooning may be implicated in PCF development. Hepatic stellate cell (HSC)
activation is likely affected by centrilobular inflammation.
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Abbreviations
ASH Alcoholic steatohepatitis
α-SMA Alpha-smooth muscle actin
CPV Central perivenulitis
CVE Central vein endotheliitis
CLF Centrilobular fibrosis
CPA Collagen proportionate area
DIA Digital image analysis
DSAs Donor-specific antibodies
DR Ductular reaction
HCV Hepatitis C virus
HSCs Hepatic stellate cells
K7 Keratin 7
LT Liver transplantation
NASH Non-alcoholic steatohepatitis
NRH Nodular regenerative hyperplasia
MMF Mycophenolate mofetil
PCF Pericellular fibrosis
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Introduction
Sinusoidal fibrosis (SF) and pericellular fibrosis (PCF) are
frequently observed in steatohepatitis of alcoholic and non-
alcoholic aetiology [40]. They have also been reported as a
frequent feature in the early phase of fibrosing cholestatic
hepatitis C [10]. Post-transplant centrilobular fibrosis (CLF),
most likely resulting from organisation of prior central
perivenulitis lesions, has been mainly examined in paediatric
recipients and chronic rejection has been implicated in its
development [11, 14, 32, 42]. In adult post-transplant liver,
periportal SF has been linked to recurrent hepatitis C [30].
Nevertheless, the significance of SF in adult post-transplant
liver remains largely unexplored, while PCF in post-transplant
liver has not previously been investigated.
Hepatic stellate cells (HSCs) are the main liver cells re-
sponsible for extra-cellular matrix deposition and their activa-
tion plays a role in the development of SF, CLF and PCF [3].
However, the role of HSCs has not been studied in detail in
post-transplant liver [5, 16, 43] and their activation has mainly
been assessed in association with fibrosis progression in re-
current hepatitis C [5, 16]. In non-alcoholic steatohepatitis
(NASH), sonic hedgehog (Shh), a member of the hedgehog
signalling pathway expressed in ballooned hepatocytes, is in-
volved in HSC activation with subsequent PCF [44].
Studies evaluating the long-term outcome of the hepatic
allograft have highlighted changes in the microvasculature,
including sinusoidal dilation and SF [6, 12, 26]. Certain drugs
are linked to SF development in the liver allograft, most no-
tably azathioprine [6, 24]. Inadequate immunosuppression
[11], preformed donor–specific antibodies [32] and chronic
antibody–mediated rejection [6] have also been proposed as
aetiological factors for SF in children. In the liver of renal
transplant recipients, SF at the ultrastructural level has been
linked to the development of portal hypertension [33].
We aimed to evaluate the frequency, extent and topography
of SF and PCF in the adult post-transplant liver and its corre-
lation with clinico-pathological features, HSC activation,
ductular reaction (DR) and patient outcome.
Materials and methods
Patient population
This single-centre, retrospective cohort study was conducted
at the Fibrosis Lab, Institute of Cellular Medicine, Newcastle
University, and the Dept. of Cellular Pathology, Royal
Victoria Infirmary, Newcastle upon Tyne, UK, on anonymised
archival histological material from post-transplant liver biop-
sies obtained between March 2010 and September 2015 at
Freeman Hospital, Newcastle upon Tyne, UK. During this
period, 192 post-transplant liver specimens were obtained
from 99 patients. Consent to use tissue for research was avail-
able for 29 patients with 59 liver specimens. Explant surgical
specimens of failed allografts and biopsies without adequate
amount of tissue material remaining in the paraffin block were
excluded. Ethical approval was obtained from local ethical
committee (Ethics approval number 10/H0906/41). No organs
from executed prisoners were used in this study.
Applying the above-mentioned criteria, 52 core liver biop-
sies obtained where clinically indicated from 28 patients (12
men and 16 women), who had undergone a total of 29 liver
transplantations, were available for the study. Mean age was
49.3 years (range 33–67) and median period of follow-up was
30 months (range 7–96). Median time to biopsy was 22 (in-
terquartile range 9–35) days. Donors were 11 men, 18 women
and one of unknown gender with average age at donation
51 years (range 24–80). Demographic details and results of
liver function tests at time of biopsy, drug and medical history,
indications of LT, presence and class of preformed donor–
specific antibodies (DSA) and any other relevant details dur-
ing follow-up were obtained from the hospital records and are
summarised in Table 1.
Histopathologic assessment
Archival haematoxylin & eosin-stained slides were centrally
reviewed by two histopathologists (SAB, DT). Sections were
assessed for features of allograft rejection (including portal
inflammation, bile duct injury, portal vessel endotheliitis, cen-
tral perivenulitis and central vein endotheliitis) and graded
using the Banff criteria [1], while interface hepatitis, lobular
inflammation and confluent necrosis were assessed and grad-
ed according to the modified necro-inflammatory activity
grading scheme [21]. All types of cholestasis (hepatocellular,
canalicular and ductular) were graded 0–3 according to inten-
sity and extent (0 = absent, 1 = mild, 2 = moderate, 3 = se-
vere). Hepatocyte ballooning was scored 0–2 (0 = absent,
1 = few, 2 = many hepatocytes) [3]. Ischaemic changes (sinu-
soidal dilatation and congestion) were graded according to
their extent (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
The presence of granulomas, mitotic figures and
microabscesses was also assessed.
Sections, 4 μm thick, were cut from each block and stained
with Sirius red fast green (SRFG) stain for the assessment of
fibrosis and collagen proportionate area (CPA). Sinusoidal
fibrosis (SF) was semi-quantitatively scored 0–2 (0 = absent,
1 = delicate SF, 2 = dense) to reflect the extent and thickness
of sinusoidal fibrosis seen in adult liver allograft biopsies,
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which involved < 50% of sinusoids in the biopsies studied.
Portal fibrosis and centrilobular fibrosis were scored (0–3)
according to the histologic system proposed by Venturi et al.
[41]. A summative fibrosis score was generated (0–8) by com-
bining the three scores. PCF was diagnosed when collagen
fibres surrounded individual hepatocytes or cords of hepato-
cytes in a Bchicken-wire^ pattern. PCF was assessed for pres-
ence and topography (centrilobular only, zones 3 & 2,
panlobular). In this study, centrilobular fibrosis will refer to
the mere presence of SF in centrilobular areas, regardless of its
occurrence in other hepatic lobular zones, whereas isolated
CLF will refer to SF restricted to zone 3.
Immunohistochemical staining and assessment
A total of 4-μm-thick sections were immunostained for α-
smooth muscle actin (α-SMA) to assess HSC activation and
keratin 7 to assess DR and biliary metaplasia. For α-SMA
immunostaining, sections were deparaffinised and rehydrated
followed by standard endogenous peroxidase blocking. Heat-
induced epitope retrieval (HIER) was performed using citrate-
based antigen unmasking solution (Vector Laboratories Inc.,
Newcastle, UK) for 20 min. Avidin and biotin blocks were
applied for 20 min each and a casein block was applied for 1 h
(Vector Laboratories Inc., Newcastle, UK). The slides were
then incubated for 1 h with a mouse monoclonal, anti-α-
SMA antibody (FITC, Sigma-Aldrich, UK) diluted 1:3000
with 1% Casein block added. Slides were incubated for 2 h
with biotinylated anti-fluorescein raised in goat, which was
diluted 1:300 followed by incubation with ABC reagent,
R.T.U. Vectastain kit (Vector Laboratories Inc., Newcastle,
UK) for 1 h. Similar steps were used to immunostain sections
for keratin 7 with a mouse monoclonal anti-human keratin 7
(clone OV-TL 12/30, Dako AS, Denmark) at 1:200 dilution at
the automated immunostainer Ventana Benchmark®XTusing
the XT ultraView detection kit (Roche Diagnostics, USA). A
subgroup of cases (n = 20) had been routinely immunostained
for C4d with a rabbit monoclonal anti-C4d (clone A24-T) DB
Biotech (Košice, Slovakia) at 1:200 dilution using the same
automated method as above. Sections of cases with ballooned
hepatocytes (n = 5) and of cases without ballooned hepato-
cytes used as controls (n = 4) were immunostained with a
rabbit monoclonal antibody to sonic hedgehog (Shh) (anti-
Shh ab53281, Αbcam, UK) at 1:3000 dilution with overnight
incubation 4 °C using the Novolink™ Max Polymer
Detection System (RE7280-K, Leica Biosystems Inc., UK).
3,3′-diaminobenzidine (DAB) was used as chromogen (Vector
Laboratories Inc., Newcastle, UK). All slides were counter-
stained with Mayer’s Haematoxylin, dehydrated with alcohol,
cleared in clearene and cover-slipped using Pertex (Histolab,
Askim, Sweden).
Keratin 7 immunostained sections were assessed for the
extent of ductular reaction (DR) using the scoring system
Table 1 Summary of clinical details and laboratory results of the 28
study patients, 2 of which had undergone 2 liver transplantations (30
transplanted livers in total)
Features
Indication for liver transplantation (n = 28) n (%)
PBC 8 (28.6)
PSC 5 (17.9)
ALD 5 (17.9)
NASH/HCC 2 (7.1)
Drug related 2 (7.1)
Hepatitis (viral and autoimmune) 2 (7.1)
Surgical indications 3 (10.7)
Cryptogenic 1 (3.6)
Preformed donor–specific antibodies (n = 28)
Present 6 (21.4)
Class I (A1, A3, B8) 4 (14.3)
Class II (DQ3, DQ7) 2 (7.1)
Absent 22 (78.6)
Complications and follow-up data (n = 28)
HCC in the explant 4 (14.3)
Biliary complications 8 (28.6)
Vascular complications 9 (32.1)
Combined biliary and vascular complications 1 (3.6)
Post-operative sepsis 1 (3.6)
Allograft failure due to PSC recurrence 1 (3.6)
Death during follow-up 4 (14.3)
Cardiac causes 3 (10.7)
Acute pancreatitis 1 (3.6)
T2DM 4 (14.3)
Azathioprine therapy 18 (64.3)
Type of allograft (n = 29*)
DBD 25 (86.2)
DCD 4 (13.8)
Allograft size (n = 29*)
Whole liver 27 (93.1)
Reduced size (split) 2 (6.9)
Ischaemia duration in min (n = 29*) X̅ ± SD
Total cold ischaemia 580.03 ± 135.73
Recipient warm ischaemia 51.55 ± 16.79
Liver function tests at the time of biopsy X̅ ± SD
ALT (IU/L) 277.3 ± 293.04
Alkaline phosphatase (IU/L) 371.3 ± 240.08
Total bilirubin (μmol/l) 86.2 ± 103.87
Numbers and percentages are expressed in relation to number of available
data as indicated by the n value beside each feature
*One patient out of the 28 included in the study underwent a 2nd liver
transplantation due to failure of the 1st allograft (recurrent PSC)
SD standard deviation, PBC primary biliary cholangitis, PSC primary
sclerosing cholangitis, ALD alcoholic liver disease, NASH non-alcoholic
steatohepatitis, HCC hepatocellular carcinoma, DSA pre-transplant
donor–specific HLA antibodies, DBD donation after brain death, DCD
donation after circulatory death, T2DM type 2 diabetes mellitus
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devised by Gadd et al. [15] with slight modification (0–3,
where 0 = absent, 1 = focal increased DR in portal tracts
(PT) involving < 50% of PT circumference, 2 = DR in PT
involving > 50% of PT circumference, 3 = distinct spurs of
DR extending into the lobule). C4d immunostaining was
assessed in the sinusoids, portal microvessels and portal stro-
ma as absent, present when strong and diffuse or equivocal
when mild and focal. Intralobular K7–positive cells with he-
patic progenitor cell morphology, K7-positive hepatocytes
and Shh-positive hepatocytes were semi-quantitatively scored
0–2 (0 = absent, 1 = few positive hepatocytes and 2 =many
positive hepatocytes) and their acinar topography was
recorded.
Morphometric analysis for SRFG and α-SMA stains
Slides stained with SRFG and anti-α-SMA were
photographed using a Nikon ECLIPSE Ni-U (Nikon UK
Ltd) microscope. At least 15 optical fields were captured for
SRFG and α-SMA-stained slides at × 10 magnification. CPA
and percentage of α-SMA-stained area were quantified using
Nikon Imaging Software Elements Basic Research (NIS-
Elements BRAnalysis 4.12.01, Nikon UK Ltd) and both were
expressed as a percentage of parenchymal total area.
Statistical methods
Values are expressed as percentages and measures of central
tendency [mean (X̅), standard deviation (SD), median and
range]. Chi square (χ2) test was used to compare categorical
data. For comparison between 2 groups, MannWhitneyU test
for non-parametric samples was used. Associations between
variables were studied with non-parametric Spearman’s rank
correlation coefficient (rho). Significant correlations were il-
lustrated by means of linear regression. Stepwise multivariate
regression analysis was used to identify most significant pre-
dictors of CPA and HSC activation. Correlations between al-
lograft fibrosis, HSC activation parameters and duration of
ischaemia were done by means of analysis of covariance
(ANCOVA) with time since liver transplantation as the fixed
variable. The probability (p) value was considered significant
at a level < 0.05 and highly significant when p < 0.001. All
statistical analyses were done using IBM SPSS Statistics soft-
ware, version 23.0 (IBM Corp, Armonk, New York, USA).
Results
Histopathology
The median biopsy length was 18.5 mm (range 3–33mm) and
the median number of portal tracts per biopsy was 10 (range
3–24). The main histopathologic findings and diagnosis are
described in Table 2. In all but one case, the clinical indication
for liver biopsy was to investigate graft dysfunction. In the
remaining case, liver biopsy was undertaken to help determine
the need for antiviral therapy after LT for chronic hepatitis C.
Thirty-six out of the 52 (69.2%) biopsies showed SF. Most
of the biopsies with SF (20/36, 55.6%) exhibited CLF. In half
of the cases with CLF (n = 10), this was restricted in zone 3.
PCF was seen in 7/52 (13.5%) biopsies and only in those with
CLF (7/20, 35%) (Table 2). PCF was centrilobular in five
biopsies, involved zones 2 & 3 in one biopsy and was
panlobular in one biopsy. SF, CLF and PCF were present in
biopsies from 19 (67.9%), 13 (46.4%) and 5 patients (17.9%),
respectively. Significant correlations between centrilobular in-
flammatory changes and histopathologic features of acute cel-
lular rejection are shown in Supplementary Table S1.
Immunohistochemical and morphometric results
and their correlation with histological and clinical
data
The results of collagen proportionate area (CPA), per-
centage of α-SMA-stained area and summative fibrosis
score are summarised in Table 3 along with significant
correlations associated with each variable. Figure 1
shows representative images of cases with centrilobular
fibrosis (a, d and b, e), sinusoidal fibrosis (c and f) and
pericellular fibrosis (1G-I) stained with SRFG (a, b, c
and g) or α-SMA (d–f, h).
Summative fibrosis score and CPA were significantly
higher in cases with SF (p < 0.001 for both), CLF (p < 0.001
and p = 0.031, respectively) and PCF (p < 0.001 and p =
0.015, respectively) (Fig. 2a–f). α-SMA-positive area was
only significantly higher in cases with CLF (p = 0.044)
(Fig. 2g). Neither CPA nor summative fibrosis score had any
significant correlation with α-SMA-positive area. Cases
exhibiting SF without CLF did not show any statistically sig-
nificant differences in CPA, summative fibrosis score or α-
SMA-positive area when compared with cases showing CLF
in association with parenchymal SF (p = 0.149, 0.559 and
0.372, respectively). CLF was significantly correlated with
confluent necrosis (p = 0.003).
A significant association was found between hepatocyte
ballooning and canalicular cholestasis (p < 0.001), hepatocel-
lular cholestasis (p = − 0.004) and PCF (p = 0.019) (Fig. 3a,
c, d). Shh immunohistochemical expression (Fig. 4) was sig-
nificantly associated with hepatocyte ballooning (p < 0.001),
the presence of DR (p = 0.02), SF (p = 0.036) and hepatocel-
lular cholestasis (p = 0.02). A significant association was also
found between PCF and canalicular cholestasis (p = 0.022),
indicating a correlation between PCF and hepatocellular bal-
looning of cholestatic origin (Fig. 3a, b). Sinusoidal conges-
tion alone was associatedwith less hepatocyte ballooning (p =
0.031); however, neither sinusoidal congestion nor dilatation
236 Virchows Arch (2019) 475:233–243
had any significant association with PCF. CLF and PCF were
associated with longer time since liver transplantation (p =
0.014 and p = 0.043, respectively).
Portal fibrous expansion score showed a highly significant
linear correlation with DR grade (p < 0.001), a significant cor-
relation with biliary metaplasia and an inverse linear correla-
tion with interlobular keratin 7–positive cells with hepatic
progenitor cell morphology. C4d immunostaining results (si-
nusoidal, portal microvascular or portal stromal) were
Table 2 Detailedhistopathological results in the studied liver biopsies (n=52)
Feature Present n (%)
Sinusoidal fibrosis 36 (69.2)
Delicate 26 (50)
Dense 10 (19.2)
Centrilobular fibrosis1 20 (38.5)
Mild 6 (11.5)
Moderate 12 (23.1)
Severe 2 (3.8)
Pericellular fibrosis 7 (13.5)
Centrilobular only 5 (9.6)
Zones 3 & 2 1 (1.9)
Panlobular 1 (1.9)
Acute cellular rejection (ACR) 38 (73.1)
Mild 7 (13.5)
Moderate 19 (36.5)
Severe 12 (23.1)
Portal inflammation 47 (90.4)
Mild 17 (32.7)
Moderate 15 (28.8)
Severe 15 (28.8)
Bile duct injury 43 (82.7)
Mild 21 (40.4)
Moderate 18 (34.6)
Severe 4 (7.7)
Portal endotheliitis 40 (76.9)
Mild 18 (34.6)
Moderate 13 (25)
Severe 9 (17.3)
Central perivenulitis 24 (46.2)
Mild 13 (25)
Moderate 10 (19.2)
Severe 1 (1.9)
Central vein endotheliitis 26 (50)
Mild 14 (29.6)
Moderate 5 (9.6)
Severe 7 (13.5)
Hepatocyte ballooning 5 (9.6)
Few 2 (3.8)
Many 3 (5.8)
Sinusoidal dilatation 39 (75)
Mild 35 (67.3)
Moderate 4 (7.7)
Severe 0 (0)
Sinusoidal congestion 29 (56.8)
Mild 27 (51.9)
Moderate 2 (3.8)
Severe 0 (0)
Lobular inflammation 50 (96.1)
Grade 1 13 (25)
Grade 2 23 (44.2)
Grade 3 13 (25)
Grade 4 1 (1.9)
Confluent necrosis 28 (53.8)
Grade 1 10 (19.2)
Grade 2 12 (23.1)
Grade 3 6 (11.5)
Grades 4–6 0 (0)
Interface hepatitis 18 (34.6)
Grade 1 15 (28.8)
Grade 2 2 (3.8)
Grade 3 1 (1.9)
Grade 4 0 (0)
Hepatocellular cholestasis 40 (76.9)
Mild 30 (57.7)
Moderate 8 (15.4)
Severe 2 (3.8)
Table 2 (continued)
Canalicular cholestasis 8 (15.4)
Mild 5 (9.6)
Moderate 2 (3.8)
Severe 1 (1.9)
Ductular cholestasis 1 (1.9)
Moderate 1 (1.9)
Portal fibrous expansion 32 (61.5)
Mild 18 (34.6)
Moderate 13 (25)
Severe 1 (1.9)
Ductular reaction extent 34 (65.4)
Mild 20 (38.5)
Moderate 7 (13.5)
Severe 7 (13.5)
Biliary metaplasia (K7+ hepatocytes) 14 (73.1)
Few 8 (15.4)
Many 6 (11.5)
K7+ cells with HPC morphology2 18 (34.6)
Few 17 (32.7)
Many 1 (1.9)
Other features
Mitotic figures 7 (13.5)
Microabscesses 16 (30.8)
Granulomas 23 (44.2)
C4d immunostaining (n = 20)3
Portal stroma 9 (45)
Portal microvessels 4 (20)
Sinusoids 4 (20)
Main histological diagnosis
ACR 38 (73.1)
Ascending cholangitis 1 (1.9)
Recurrent hepatitis C 1 (1.9)
Preservation/reperfusion injury 1 (1.9)
Other and inconclusive
diagnoses4
7 (13.5)
Venous outflow obstruction 4 (7.7)
Isolated 1 (1.9)
With ACR 1 (1.9)
With ductopenia 2 (3. 8)
ACR acute cellular rejection, CPV central perivenulitis, CVE central vein
endotheliitis, K7+ keratin 7-positive
1 Only detected in biopsies showing SF; however, the ratios were given in
relation to the total number of biopsies studied (n = 52)
2 Intra-acinar K7+ cells with hepatic progenitor cell morphology
3 The presence of C4d immunostaining was only assessed in a subgroup
group of biopsies and percentages are given in relation to this subgroup
(n = 20) and not the total number of biopsies (n = 52)
4 These included inconclusive findings, cholestasis and granulomatous
hepatitis
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available for 20 cases and there was no significant association
with SF, CLF or PCF independent of topography.
Multivariate regression analysis highlighted confluent ne-
crosis as the most significant predictor for HSC activation
(assessed by α-SMA-positive area), whereas time since liver
transplantation proved to be the most significant predictor of
CPA followed by CLF grade. The most significant predictors
of the summative fibrosis score were CLF grade, SF extent
and DR score (Table 3).
SF, PCF and α-SMA-positive area scores were indepen-
dent of patient age or gender, donor’s age or gender, indication
for liver transplantation, liver function test values, rejection
type, pre-transplant donor–specific antibodies or biliary/
vascular complications.
Almost half of biopsies (17 biopsies, 47.2%), exhibiting
SF, were receiving azathioprine at the time of biopsy, com-
pared to 6 biopsies only (37.5%), who did not exhibit SF, with
no statistically significant differences (odds ratio 1.5741, p =
0.462). Similarly, mycophenolate mofetil (MMF) was admin-
istered by 44.4% (n = 16) of biopsies showing SF, and 56.25%
(n = 9) of SF-negative biopsies (odds ratio 0.7778, p = 0.638).
Administration of both medications does not appear to be
associated with any statistically significant difference in sum-
mative fibrosis score, CPA or α-SMA-positive area.
Duration of ischaemia did not correlate with liver allograft
fibrosis markers (summative fibrosis score and CPA) nor with
α-SMA-positive area; however, cases exhibiting PCF were
associated with longer warm ischaemia duration (X̅ = 69.14
vs 49.8 min, p = 0.009), and so did CLF-positive cases
(X̅ = 57.3 vs 49.26 min, p = 0.05).
Discussion
To our knowledge, this is the first study to extensively inves-
tigate sinusoidal fibrosis (SF) and pericellular fibrosis (PCF)
and their relation to hepatic stellate cell activation in adult
post-transplant livers. We showed that SF is a common find-
ing in adult post-transplant livers, existing in more than two
thirds of the studied biopsies and had a predilection for
centrilobular areas. Although SF has previously been reported
in a variety of liver disorders, post-transplant SF was rarely
mentioned in adult post-transplant liver: periportal SF in the
context of recurrent hepatitis C has been reported as a marker
of accelerated post-transplant recurrence [30], and as one of
the suggested criteria for diagnosing fibrosing cholestatic hep-
atitis C [45]. In contrast, SF has been extensively studied in
paediatric post-transplant liver where the presence of CLF
ranged from 10.3 [31] to 95%; however, isolated CLF was
seen in only 5% of the cases in the latter series [42]. In our
study, isolated CLF is much more prevalent (50% of biopsies
exhibiting CLF).
Table 3 Significant correlations of collagen proportionate area, summative fibrosis score and α-SMA-stained area with results of multivariate analysis
(most significant dependent variables) on the right side of the Table
Feature Mean ± SD Median (range) Significant correlations Multivariate analysis
Variable rho p Dependent variable Coefficient (β) p
CPA 1.61 ± 2.384 0.66 (0.01–12.97) Time since LT 0.282 0.043*
Summative fibrosis
score
0.49 < 0.001** (intercept) 0.7177
CLF grade 0.324 0.019* Time since LT 0.002782 0.0001**
SF extent 0.504 < 0.001** CLF grade 0.7665 0.01*
Summative
fibrosis score
2.46 ± 1.841 2 (0–8) Time since LT 0.341 0.013*
CPA 0.49 < 0.001** (intercept) 0.2134
Biliary metaplasia 0.346 0.012* CLF grade 0.9726 < 0.0001**
DR grade 0.336 0.015* SF extent 1.2771 < 0.0001**
CLF grade 0.591 < 0.001** DR grade 0.4390 < 0.0001**
SF extent 0.801 < 0.001**
Portal fibrosis 0.753 < 0.001**
α-SMA% 1.54 ± 1.301 1.07 (0–4.71) CLF grade 0.32 0.021*
RAI 0.318 0.022* (intercept) 1.0536
CPV 0.331 0.017* Confluent necrosis 0.4843 0.003*
CVE 0.370 0.007*
Confluent necrosis 0.519 < 0.001**
CPA collagen proportionate area, α-SMA% percentage ofα-SMA-stained areas, CLF centrilobular fibrosis, SF sinusoidal fibrosis,DR ductular reaction,
RAI rejection activity index (BANFF score),CPV central perivenulitis,CVE central vein endotheliitis, LT liver transplantation, rho correlation coefficient
*Significant
**Highly significant
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In fact, CLF appears to be a more progressive form of SF, as
supported by our finding of longer time since liver transplanta-
tion (LT) in cases with CLF. This is re-enforced by the strong
correlation between time since LTand both CPA and summative
fibrosis score and the fact that time since LT and CLF severity
were the most significant predictors of CPA in our study. CPA is
significantly correlated with hepatic venous pressure gradient,
used as a measure of portal hypertension [20, 28, 29]. Ling et al.
[27] have reported results supportive of such theory with portal
hypertension–related complications identified by imaging in al-
most half of the paediatric population in their study. Indeed,
progressive graft fibrosis occurs in paediatric recipients, [13,
36] with cirrhosis developing in 15% of the cases [13]. Along
these lines, Venturi et al. showed increasing liver allograft fibro-
sis score (LAFSc) with time in paediatric transplant biopsies.
Our results showing timely progression of allograft fibrosis
(by both the summative fibrosis score and CPA) suggest that
similar changes are likely to take place in adult recipients indi-
cating that longer period of follow-up may be advisable.
Sinusoidal fibrosis has been described in ageing animal
[18] and human [25] livers. Centrilobular SF is the character-
istic pattern of early fibrosis in alcoholic steatohepatitis (ASH)
and adult NASH. The effects of reactive oxygen species
(ROS) and oxidative stress underlie the pathogenesis of SF
in NASH [34, 39] and ageing liver [8, 37]. Replicative
senescence resultant in telomere attrition is the classic theory
of ageing [4, 22]. Both mechanisms appear to be intertwined
[7]. Liver cells are susceptible to senescence and stress-related
senescence can be accelerated by the stress of transplantation.
Cellular senescence is suggested to be accountable for some of
the long-term deterioration and damage of liver allografts
[19]. Aini et al. [2] demonstrated telomere shortening in
transplanted livers of paediatric recipients.
A vascular aetiology for the development of SF in post-
transplant liver cannot be excluded. Features of venous out-
flow obstruction have been reported in the right lobe of live
donor transplanted livers after volume restoration [38]. Mild
SF related to hepatocyte atrophy may be seen in nodular re-
generative hyperplasia (NRH), whereas fibrosis typical of
chronic liver disease is usually absent [35]. SF could also
reflect changes in sinusoidal blood flow, similar to what oc-
curs in NRH. NRH may be seen de novo in post-transplant
biopsies [9].
Only three studies have investigated the role of activated
HSC in post-transplant livers to date [5, 16, 42], two of which
focused on recurrent hepatitis C. Gawrieh et al. [16] conclud-
ed that HSC activation could predict progression of fibrosis in
recurrent HCV infection. Cisneros et al. [5] reported a correla-
tion between HSC activation and rate of fibrosis progression in
patients with recurrent HCV post-transplant; however, they did
Fig. 1 Serial sections of two
cases with centrilobular fibrosis
(a, d and b, e), a mild ACR case
with non-zonal sinusoidal fibrosis
(c and f) and a case with
pericellular fibrosis (G-I): A, B, C
& G. Sinusoidal collagen (black
arrows, SRFG stain) and D-F, H.
activated HSC (cyan arrows, α-
SMA (immunohistochemical
stain). I. Ballooned hepatocytes
with associated fibrosis (arrows)
in a case with canalicular chole-
stasis (arrowheads). Absence of
fibrosis in relation to normal-
sized hepatocytes (thick arrows)
(SRFG), CV= central venule
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not show any difference in HSCs activation and accelerated
fibrosis as compared to non-LT patients with chronic hepatitis
C. Venturi et al. [42] reported that ≥ 8% activated HSCs (α-
SMA%) at 6-month post-transplant in paediatric patients is an
independent risk factor for 7-year fibrosis development and
thatα-SMA% ≥ 8% at 3-year post-transplant is associated with
fibrosis development at 7 years. None of these studies investi-
gated HSCs correlation with SF or CLF. However, in our study
with only one HCV–infected patient, α-SMA% has not
exceeded 4.71% and we did not encounter any correlation
betweenα-SMA% and allograft fibrosis parameters apart from
that with CLF. Conversely, α-SMA% was highly significantly
correlated with centrilobular inflammatory changes, either in-
volving central veins or adjacent hepatocytes. Activated HSCs,
as well as being a key player in fibrogenesis, also help to
activate and promote hepatic epithelial cell regeneration. A
variety of stimulants including growth factors and cytokines
are involved in the process of HSC activation in response to
hepatic injury [46]. Centrilobular hepatocytes expressing glu-
tamine synthetase were shown to be the last cells to proliferate
in the process of liver regeneration [17], as well as being the
most vulnerable to oxidative stress due to their poor oxygen
supply. This may explain the predilection of SF to centrilobular
regions, as the delayed proliferation of these cells, in the setting
of activated HSCs, may allow more collagen fibres to be de-
posited in centrilobular regions during healing.
PCF affecting perivenular (zone 3) hepatocytes, also known
as Bchicken-wire^ fibrosis, is typically seen in both ASH and
Fig. 2 Graphs show correlations between measures of allograft fibrosis
[summative fibrosis score and collagen proportionate area (CPA)] and
hepatic stellate cell activation (α-SMA%) with patterns of allograft
fibrosis in parenchyma [sinusoidal fibrosis (SF), centrilobular fibrosis
(CLF) and pericellular fibrosis (PCF)], in study cohorts (n = 52). Data
are presented as medians and quartile intervals. a–c CPA was higher in
cases with SF (a), CLF (b) and PCF (c). d–f Summative fibrosis score
was higher in cases with SF (d), CLF (e) and PCF (f). g α-SMA% was
higher only in cases exhibiting CLF
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NASH [40]. We have assessed for the first time PCF in adult
post-transplant liver and highlighted a significant association
between its presence and hepatocyte ballooning of cholestatic
aetiology. In addition, ballooned hepatocytes in all cases were
positive for Shh, including the two biopsies with PCF. The
correlation of Shh expression with SF in our small cohort can
be explained by the role of hedgehog signalling pathway in
HSC activation. The recently exposed role of HSC activation
in the metabolic zonation of the liver may also underlie the
predilection of PCF in zone 3 in our study as well as in other
liver disorders [23]. Our study is the first to show that Shh is
expressed in ballooned hepatocytes of cholestatic aetiology.
The main limitations of our study include the lack of pro-
tocol biopsies, very small number of recipients of reduced-
sized grafts and very small number of recurrent hepatitis C
cases. However, ours was a single-centre study and we follow-
ed a non-biased approach in our sampling protocol.
Regardless of these limitations, we have demonstrated the
frequent presence of SF in adult post-transplant liver and its
predilection to centrilobular areas. We could not show any
short-term effects of SF or CLF on the liver allograft;
Fig. 3 Significant associations of pericellular fibrosis (PCF) and hepatocyte ballooning of cholestatic origin. a and b PCF was significantly associated
with ballooning and canalicular cholestasis. c and d Ballooning significantly associated with canalicular and hepatocellular cholestasis
Fig. 4 Shh immunostaining in a case with severe ACR and cholestasis
(×200)
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however, our results support a progressive development of
these fibrotic processes. A longer observation period may
highlight possible long-term effects of SF and CLF.
Moreover, while PCF was not a common finding, we showed
a correlation of PCF with Shh-expressing ballooned hepato-
cytes indicating a possible involvement of the Shh pathway in
the pathogenesis of PCF in the liver allograft that warrants
further in-depth investigation at the molecular level.
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